Biotoxtech Co., Ltd.
Financials
Valuation Metrics
Biotoxtech Co., Ltd.'s Market Cap is ₩352B. At end of 2025 it was ₩449B. Ranked #1962 of 2,436 in KR market (top 81%), #1230 of 1,649 on KOSDAQ (top 75%), #211 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 35.19B KRW | KR#1,962/2,436 Sec#211/234 |
| Revenue | 47.64B KRW | KR#1,809/2,436 Sec#126/234 |
| Net Income | -2.23B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 130.06B KRW | KR#1,567/2,436 Sec#125/234 |
| Net Assets | 29.25B KRW | KR#2,171/2,436 Sec#194/234 |
| Employees | 230 | KR#984/2,436 Sec#83/234 |
| Value | ||
| P/B | 1.20x | KR#1,640/2,436 Sec#112/234 |
| P/S | 0.74x | KR#1,190/2,436 Sec#60/234 |
| FCF Yield | 12.83% | KR#527/2,436 Sec#18/234 |
| Profitability | ||
| ROE | -7.61% | KR#1,831/2,436 Sec#139/234 |
| ROA | -1.71% | KR#1,674/2,436 Sec#119/234 |
| Op. Margin | -10.94% | KR#2,004/2,436 Sec#135/234 |
| Revenue Growth | 5.51% | KR#1,140/2,436 Sec#106/234 |
| Financial Health | ||
| Debt Ratio | 444.69% | KR#2,277/2,436 Sec#225/234 |
| Total Debt | 36.45B KRW | KR#1,105/2,436 Sec#82/234 |
| FCF | 4.52B KRW | KR#923/2,436 Sec#64/234 |
| Cash | 15.52B KRW | KR#1,396/2,436 Sec#106/234 |
| Current Ratio | 0.53x | KR#2,238/2,436 Sec#213/234 |
| Performance | ||
| 1Y Return | -24.74% | KR#1,433/2,436 Sec#123/234 |
| 1M Return | 0.68% | KR#816/2,436 Sec#73/234 |
| From 52W High | -46.42% | KR#1,035/2,436 Sec#82/234 |
| 1Y MDD | -49.48% | KR#905/2,436 Sec#72/234 |
| Trading | ||
| Volume | 28,548 shares | KR#1,674/2,436 Sec#164/234 |
| Foreign Own. | 1.96% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 48 KRW | KR#1,453/2,436 Sec#102/234 |
| BPS | 2,486 KRW | KR#1,911/2,436 Sec#152/234 |
Company Info
The company, a non-clinical CRO specialist listed on KOSDAQ in 2007, owns the subsidiary KiforPrime Research. It performs toxicity, safety, and efficacy evaluations for medicines, cell therapies, gene therapies, and chemicals, providing professional contract research services through GLP certification. In line with global industry trends, the company is expanding primate non-clinical trials and pursuing innovation by establishing experimental animal facilities and offering consulting services. Biotoxtech was established in 2000 and is headquartered in Chungcheongbuk-do, Cheongju-si.